Miraqules is investing efforts to make its products ubiquitously available and be the most trusted and desired choice in the wound care domain. Miraqules’ clinically validated and patented technology has been designed to treat wounds of any severity, i.e., wounds ranging from minor abrasions to acute, severe traumatic injuries, and for use in intra-operative or post-operative hemostasis. The core technology of Miraqules is a scientifically designed manual process to produce fibrous compounds at room temperature using different biomaterial proportions, eliminating the conventional and expensive electrospinning technique. The innovative approach allows for the creation of fibrous compounds through a strong Coulomb interaction, which eliminates the need for any chemical crosslinking agent (as in the electrospinning technique), thereby reducing any potential toxicity or other undesirable effects.